Thankfully, there are currently two RSV vaccines approved by the Food and Drug Administration to help people protect against the virus: Arexvy by GlaxoSmithKline and Abrysvo by Pfizer. The Centers for ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...
The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
Controller medications, also known as daily maintenance medications, are a critical tool for managing asthma — reducing daily ...
Gabapentinoids -- pregabalin and gabapentin -- were tied to increased hip fracture risk in older adults. Gabapentinoids -- ...
Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s ...
Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback